European Union Drugs Regulator, European Medicines Agency (EMA), recently announced that it has approved AstraZeneca’s Covid-19 vaccine, Vaxzevria, to be used as third dose booster jab in adults.
“Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA Covid-19 vaccine,” EMA said in a statement.
Explaining the reason for granting its approval, EMA also said, “There was substantial body of evidence demonstrating an increased immune response after a third dose booster with Vaxzevria.”
This dose was developed by the pharma major alongside University of Oxford.
In December last year, when first Omicron infections had started appearing, AstraZeneca stated that research is underway for developing an Omicron-specific vaccine. “Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data,” the statement read.
